Literature DB >> 16957410

Fasting and post-prandial glycemia and their correlation with glycated hemoglobin in Type 2 diabetes.

M Monami1, C Lamanna, L Lambertucci, R Longo, C Cocca, F Addante, E Lotti, G Masotti, N Marchionni, E Mannucci.   

Abstract

OBJECTIVE: The relative contribution of fasting and post-prandial glucose to glycated hemoglobin (HbA1c) is controversial. In the present study, we assessed the relationship with HbA1c of fasting and post-prandial glucose measured in a more naturalistic setting, through home glucose self-monitoring or with a continuous glucose monitoring system (CGM).
MATERIALS AND METHODS: A consecutive series of 300 patients with Type 2 diabetes were enrolled in the study, provided that they performed blood glucose self-monitoring. HbA1c and fasting plasma glucose (FPG) were measured at enrolment.
RESULTS: Both fasting plasma and capillary glucose showed a significant correlation with HbA1c (r=0.66 and 0.61, respectively; p<0.001). When home glucose monitoring was considered, both mean fasting and post-prandial glucose showed a significant correlation with HbA1c (r=0.71 and 0.73, respectively). In patients in the lower tertile of body mass index (BMI), HbA1c showed a significant correlation at multivariate analysis with post-prandial glucose, but not with fasting glucose. In patients with HbA1c >7%, both fasting and post-prandial glucose showed a significant correlation, after adjustment for age and BMI, with HbA1c (both p<0.01); conversely, in those with HbA1c < or =7%, such a correlation could be observed for fasting (p<0.01), but not for post-prandial glucose.
CONCLUSION: In conclusion, both fasting and post-prandial glucose contribute to the determination of HbA1c . Home glucose self-monitoring appears to provide a more accurate assessment of metabolic control than a single plasma glucose measurement in experimental conditions. Fasting glucose could provide a greater contribution to HbA1c in patients with lower HbA1c, while post-prandial glucose seems to play a major role in leaner Type 2 diabetic subjects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16957410     DOI: 10.1007/BF03344161

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  16 in total

Review 1.  The MiniMed Continuous Glucose Monitoring System (CGMS).

Authors:  J Mastrototaro
Journal:  J Pediatr Endocrinol Metab       Date:  1999       Impact factor: 1.634

2.  Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c.

Authors:  C Ito; R Maeda; S Ishida; H Sasaki; H Harada
Journal:  Diabetes Res Clin Pract       Date:  2000-12       Impact factor: 5.602

3.  Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes.

Authors:  Valeriya Lyssenko; Peter Almgren; Dragi Anevski; Roland Perfekt; Kaj Lahti; Michael Nissén; Bo Isomaa; Björn Forsen; Nils Homström; Carola Saloranta; Marja-Riitta Taskinen; Leif Groop; Tiinamaija Tuomi
Journal:  Diabetes       Date:  2005-01       Impact factor: 9.461

4.  Standards of medical care in diabetes--2006.

Authors: 
Journal:  Diabetes Care       Date:  2006-01       Impact factor: 19.112

5.  Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study.

Authors:  M Muggeo; G Zoppini; E Bonora; E Brun; R C Bonadonna; P Moghetti; G Verlato
Journal:  Diabetes Care       Date:  2000-01       Impact factor: 19.112

6.  Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control.

Authors:  E Bonora; F Calcaterra; S Lombardi; N Bonfante; G Formentini; R C Bonadonna; M Muggeo
Journal:  Diabetes Care       Date:  2001-12       Impact factor: 19.112

7.  Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis.

Authors:  O Vaccaro; G Ruffa; G Imperatore; V Iovino; A A Rivellese; G Riccardi
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

8.  Blood glucose pre-prandial baseline decreases from morning to evening in type 2 diabetes: role of fasting blood glucose and influence on post-prandial excursions.

Authors:  M Trovati; M C Ponziani; P Massucco; G Anfossi; E M Mularoni; S Burzacca; F Tassone; P Perna; M Traversa; F Cavalot
Journal:  Eur J Clin Invest       Date:  2002-03       Impact factor: 4.686

9.  Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin a1c values.

Authors:  Hans J Woerle; Walkyria P Pimenta; Christian Meyer; Niyaz R Gosmanov; Ervin Szoke; Tamas Szombathy; Asimina Mitrakou; John E Gerich
Journal:  Arch Intern Med       Date:  2004 Aug 9-23

10.  Impaired insulin sensitivity, insulin secretion, and glucose effectiveness predict future development of impaired glucose tolerance and type 2 diabetes in pre-diabetic African Americans: implications for primary diabetes prevention.

Authors:  Kwame Osei; Scott Rhinesmith; Trudy Gaillard; Dara Schuster
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

View more
  3 in total

1.  Gastric emptying, postprandial blood pressure, glycaemia and splanchnic flow in Parkinson's disease.

Authors:  Laurence G Trahair; Thomas E Kimber; Katerina Flabouris; Michael Horowitz; Karen L Jones
Journal:  World J Gastroenterol       Date:  2016-05-28       Impact factor: 5.742

2.  Fasting plasma glucose 6-12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis.

Authors:  D Karl; R Zhou; A Vlajnic; M Riddle
Journal:  Diabet Med       Date:  2012-07       Impact factor: 4.359

3.  Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting.

Authors:  David Russell-Jones; Simon R Heller; Sarah Buchs; Anna Sandberg; William J Valentine; Barnaby Hunt
Journal:  Diabetes Obes Metab       Date:  2017-07-25       Impact factor: 6.577

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.